← Leaderboards
Yogen Saunthararajah
University Of Illinois At Chicago
$12,927,987
Attributed
$20,495,437
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2008–23$2.5M$1.9M$1.3M$625K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$20,495,437 · 9
By mechanism
U01$8,344,941 · 1
P01$5,075,658 · 1
R01$3,437,785 · 2
R44$1,725,000 · 1
U54$1,059,848 · 2
R21$852,205 · 2
Top collaborators
- Zhenghong Lee8 shared
- Joseph Desimone5 shared
- James Douglas Engel5 shared
- Donald Lavelle3 shared
Most similar at University Of Illinois At Chicago
Same institution · by research overlap
- Joseph Desimone$3,651,968
- Alan P. Kozikowski$10,594,236
- Donald Lavelle$5,608,438
- Arnon Lavie$499,271
Others in their field
Top investigators on “Decitabine”
- Joseph Desimone · University Of Illinois At Chicago$7,959,474
- Jorge E Cortes · University Of Tx Md Anderson Can Ctr$5,702,737
- Jeannie T Lee · Massachusetts General Hospital$5,433,822
- Carlo M Croce · Thomas Jefferson University$4,964,858
- Timothy J Ley · Washington University$4,858,758
- Guido Marcucci · Beckman Research Institute/City Of Hope$4,606,674
Research focus
DecitabineEnzymesCellsPharmaceutical PreparationsPre-ClinicalSickle Cell AnemiaTetrahydrouridineIn VivoDoseBaseOralCytidine DeaminaseCytidine Deaminase InhibitorTumorSafetyDesignNovel TherapeuticsGenesIn VitroChemotherapyResponseEvaluationMolecular TargetResistance
Grant awards (31)
Non-cytotoxic augmentation of fetal hemoglobin and bone marrow reserves$1,023,118
P01 · FY2023 · HL · contact PI
Operationalizing DNMT1-Targeting to Treat Chemorefractory Pancreatic Cancer$221,286
R21 · FY2023 · CA · contact PI
Non-cytotoxic augmentation of fetal hemoglobin and bone marrow reserves$1,023,811
P01 · FY2022 · HL · contact PI
PET imaging of viral infection$241,500
R21 · FY2022 · AI
Operationalizing DNMT1-Targeting to Treat Chemorefractory Pancreatic Cancer$188,169
R21 · FY2022 · CA · contact PI
Non-cytotoxic augmentation of fetal hemoglobin and bone marrow reserves$1,024,639
P01 · FY2021 · HL · contact PI
Imaging Liver Cancer Proliferation$236,635
R01 · FY2021 · CA
PET imaging of viral infection$201,250
R21 · FY2021 · AI
Non-cytotoxic augmentation of fetal hemoglobin and bone marrow reserves$1,005,781
P01 · FY2020 · HL · contact PI
Imaging Liver Cancer Proliferation$141,560
R01 · FY2020 · CA
Non-cytotoxic augmentation of fetal hemoglobin and bone marrow reserves$998,309
P01 · FY2019 · HL · contact PI
A Novel, Non-Cytotoxic, Epigenetic Therapeutic for Sickle Cell Disease$750,000
R44 · FY2019 · HL
Imaging Liver Cancer Proliferation$366,848
R01 · FY2019 · CA
A Novel, Non-Cytotoxic, Epigenetic Therapeutic for Sickle Cell Disease$750,000
R44 · FY2018 · HL
Imaging Liver Cancer Proliferation$378,195
R01 · FY2018 · CA
Improving HbF induction by inhibiting epigenetic target enzymes$1,736,085
U01 · FY2017 · HL
Imaging Liver Cancer Proliferation$395,646
R01 · FY2017 · CA
A Novel, Non-Cytotoxic, Epigenetic Therapeutic for Sickle Cell Disease$225,000
R44 · FY2017 · HL
Improving HbF induction by inhibiting epigenetic target enzymes$1,736,085
U01 · FY2016 · HL
Imaging Liver Cancer Proliferation$321,679
R01 · FY2016 · CA
Improving HbF induction by inhibiting epigenetic target enzymes$1,713,169
U01 · FY2015 · HL
Improving HbF induction by inhibiting epigenetic target enzymes$1,707,550
U01 · FY2014 · HL
Improving HbF induction by inhibiting epigenetic target enzymes$1,452,052
U01 · FY2013 · HL
Optimizing decitabine regimen + formulation for nonDNA damaging DNMT1 depletion$300,166
R01 · FY2013 · CA · contact PI
Optimizing decitabine regimen + formulation for nonDNA damaging DNMT1 depletion$319,326
R01 · FY2012 · CA · contact PI
Optimizing decitabine regimen + formulation for nonDNA damaging DNMT1 depletion$319,326
R01 · FY2011 · CA · contact PI
Sickle cell scholar component$1
U54 · FY2011 · HL · contact PI
Optimizing decitabine regimen + formulation for nonDNA damaging DNMT1 depletion$329,202
R01 · FY2010 · CA · contact PI
Sickle cell scholar component$1,059,845
U54 · FY2009 · HL · contact PI
Optimizing decitabine regimen + formulation for nonDNA damaging DNMT1 depletion$329,202
R01 · FY2009 · CA · contact PI
Sickle cell scholar component$2
U54 · FY2008 · HL · contact PI